

NEW CLINICAL TRIAL OPEN FOR INCLUSION

PROTOCOL TITLE

Pembrolizumab and Radiotherapy for Oligometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study

ALIAS

PROLoNg studie

CTO NUMBER

CTOR20125EOR

SPONSOR

EORTC

KEY INCLUSION CRITERIA

Histologically confirmed HNSCC, 1-5 oligometastases (histologically or radiologically confirmed oligometastatic disease) and PD-L1 CPS ≥ 1 .

All 1-5 metastases must be amenable to SABR and eligible for treatment with pembrolizumab.

Measurable disease and ECOG performance status of 0 or 1.

Staging not older than 12 weeks

KEY EXCLUSION CRITERIA

Nasopharynx, sino-nasal, and salivary gland cancers are excluded.


In-field progression in < 6 months after curative intended locoregional irradiation.

Lesions > 6 cm*, non resected brain metastases > 4 cm or brain metastases only.

Any previous radiotherapy to any of the 1-5 metastases that would be subject to SABR.

* bone lesions > 6 cm safely amenable to SABR according to the physician, are allowed

DESIGN



PRINCIPAL INVESTIGATOR

Dr Jean-François Daisne
jeanfrancois.daisne@zas.be

STUDY COORDINATOR(S)

Kathleen Traets
kathleen.traets@zas.be

Jo Horemans
jo.horemans@zas.be